- Home
- AXS vs KNSA Comparison
AXS vs KNSA Comparison
Compare AXS & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AXS | KNSA |
|---|---|---|
| Founded | 2001 | 2015 |
| Country | Bermuda | United Kingdom |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 7.7B |
| IPO Year | 2003 | 2018 |
Fundamental Metrics
Financial Performance| Metric | AXS | KNSA |
|---|---|---|
| Price | $107.77 | $95.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 7 |
| Target Price | ★ $120.64 | $109.43 |
| AVG Volume (30 Days) | 674.7K | ★ 866.7K |
| Earning Date | 10-28-2026 | 10-27-2026 |
| Dividend Yield | ★ 1.66% | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | ★ 9.42 | 1.14 |
| Revenue | ★ $6,563,678,000.00 | $677,564,000.00 |
| Revenue This Year | N/A | $54.96 |
| Revenue Next Year | $4.03 | $24.16 |
| P/E Ratio | ★ $11.24 | $81.54 |
| Revenue Growth | 10.17 | ★ 60.09 |
| 52 Week Low | $93.02 | $37.02 |
| 52 Week High | $119.99 | $98.48 |
Technical Indicators
Market Signals| Indicator | AXS | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 68.08 | 63.18 |
| Support Level | $97.68 | $72.76 |
| Resistance Level | $107.72 | N/A |
| Average True Range (ATR) | 2.15 | 4.70 |
| MACD | 0.65 | 1.40 |
| Stochastic Oscillator | 85.95 | 81.34 |
Price Performance
Historical ComparisonAbout AXS Axis Capital Holdings Limited
Axis Capital Holdings Ltd is a specialty underwriter and provider of insurance and reinsurance solutions with operations in Bermuda, the United States (U.S.), Europe, Singapore, and Canada. The company manages its portfolio holistically, aiming to construct an optimum consolidated portfolio of funded and unfunded risks. The company's segment consists of Insurance and Reinsurance. The company generates the majority of its revenue from the Insurance segment. Geographically, the company generates the majority of its revenue from the United States, and also has its presence in Ireland, Lloyd's of London, and Bermuda.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.